Objective: Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. Design: We identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in vivo mouse models and single cell RNA-sequencing data. Results: Pretreatment transcriptome profiles differentiated patients who would become RPs or LSs on chemotherapy. Biologically, this signature originated from altered tumour-myeloid dynamics, implicating tumour-induced immune tolerogenicity with poor response to chemotherapy. The central role of the liver microenviroment was confrmed by the association of the RPLS transcriptome signature with clinical outcome in iCCA but not extrahepatic CCA, and in liver metastasis from colorectal cancer, but not in the matched primary bowel tumours. Conclusions: The RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings.

Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy / O'Rourke, Colm J; Salati, Massimiliano; Rae, Colin; Carpino, Guido; Leslie, Holly; Pea, Antonio; Prete, Maria G; Bonetti, Luca R; Amato, Francesco; Montal, Robert; Upstill-Goddard, Rosie; Nixon, Colin; Sanchon-Sanchez, Paula; Kunderfranco, Paolo; Sia, Daniela; Gaudio, Eugenio; Overi, Diletta; Cascinu, Stefano; Hogdall, Dan; Pugh, Sian; Domingo, Enric; Primrose, John N; Bridgewater, John; Spallanzani, Andrea; Gelsomino, Fabio; Llovet, Josep M; Calvisi, Diego F; Boulter, Luke; Caputo, Francesco; Lleo, Ana; Jamieson, Nigel B; Luppi, Gabriele; Dominici, Massimo; Andersen, Jesper B; Braconi, Chiara. - In: GUT. - ISSN 0017-5749. - (2023), pp. 1-13. [10.1136/gutjnl-2023-330748]

Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

Salati, Massimiliano;Bonetti, Luca R;Cascinu, Stefano;Spallanzani, Andrea;Gelsomino, Fabio;Caputo, Francesco;Dominici, Massimo;
2023

Abstract

Objective: Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. Design: We identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in vivo mouse models and single cell RNA-sequencing data. Results: Pretreatment transcriptome profiles differentiated patients who would become RPs or LSs on chemotherapy. Biologically, this signature originated from altered tumour-myeloid dynamics, implicating tumour-induced immune tolerogenicity with poor response to chemotherapy. The central role of the liver microenviroment was confrmed by the association of the RPLS transcriptome signature with clinical outcome in iCCA but not extrahepatic CCA, and in liver metastasis from colorectal cancer, but not in the matched primary bowel tumours. Conclusions: The RPLS signature could be a novel metric of chemotherapy outcome in iCCA. Further development and validation of this transcriptomic signature is warranted to develop precision chemotherapy strategies in these settings.
2023
GUT
1
13
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy / O'Rourke, Colm J; Salati, Massimiliano; Rae, Colin; Carpino, Guido; Leslie, Holly; Pea, Antonio; Prete, Maria G; Bonetti, Luca R; Amato, Francesco; Montal, Robert; Upstill-Goddard, Rosie; Nixon, Colin; Sanchon-Sanchez, Paula; Kunderfranco, Paolo; Sia, Daniela; Gaudio, Eugenio; Overi, Diletta; Cascinu, Stefano; Hogdall, Dan; Pugh, Sian; Domingo, Enric; Primrose, John N; Bridgewater, John; Spallanzani, Andrea; Gelsomino, Fabio; Llovet, Josep M; Calvisi, Diego F; Boulter, Luke; Caputo, Francesco; Lleo, Ana; Jamieson, Nigel B; Luppi, Gabriele; Dominici, Massimo; Andersen, Jesper B; Braconi, Chiara. - In: GUT. - ISSN 0017-5749. - (2023), pp. 1-13. [10.1136/gutjnl-2023-330748]
O'Rourke, Colm J; Salati, Massimiliano; Rae, Colin; Carpino, Guido; Leslie, Holly; Pea, Antonio; Prete, Maria G; Bonetti, Luca R; Amato, Francesco; Montal, Robert; Upstill-Goddard, Rosie; Nixon, Colin; Sanchon-Sanchez, Paula; Kunderfranco, Paolo; Sia, Daniela; Gaudio, Eugenio; Overi, Diletta; Cascinu, Stefano; Hogdall, Dan; Pugh, Sian; Domingo, Enric; Primrose, John N; Bridgewater, John; Spallanzani, Andrea; Gelsomino, Fabio; Llovet, Josep M; Calvisi, Diego F; Boulter, Luke; Caputo, Francesco; Lleo, Ana; Jamieson, Nigel B; Luppi, Gabriele; Dominici, Massimo; Andersen, Jesper B; Braconi, Chiara
File in questo prodotto:
File Dimensione Formato  
gutjnl-2023-330748.full.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 6.27 MB
Formato Adobe PDF
6.27 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1332010
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact